OBJECTIVE: To test the hypothesis that myocardium specific proteins may be useful markers for evaluating the severity of congestive heart failure. METHODS: Serum concentrations of myosin light chain I (MLC-I), heart fatty acid binding protein (H-FABP), creatine kinase isoenzyme MB (CK-MB), and troponin T (TnT) and plasma concentrations of brain natriuretic peptide (BNP) were determined in 48 patients with acute deterioration of congestive heart failure, both before and after effective treatment. RESULTS: Before treatment, MLC-I (mean (SEM) 3.2 (2.2) microg/l), H-FABP (9.0 (3.5) microg/l), TnT (30 (21) ng/l), and BNP (761 (303) ng/l) were higher than the normal reference range, and concentrations of CK-MB (5.4 (2.9) microg/l) were near normal. Treatment of congestive heart failure with conventional medication significantly decreased the concentrations of MLC-I (1.2 (0.3) microg/l, p < 0.0001), H-FABP (6.0 (2.0) microg/l, p < 0.0001), CK-MB (2.9 (1.5) microg/l, p < 0.0001), TnT (9 (1) ng/l, p < 0.001), and BNP (156 (118) ng/l, p < 0.0001). The decreases in H-FABP and CK-MB concentrations after treatment correlated with the decrease in BNP concentrations (p < 0.05). The absolute concentrations of MLC-I, H-FABP, CK-MB, and TnT correlated positively with those of BNP (p < 0.01). CONCLUSIONS: These findings suggest that MLC-I, H-FABP, CK-MB, and TnT may be used as reliable markers for the evaluation of the severity of congestive heart failure.
OBJECTIVE: To test the hypothesis that myocardium specific proteins may be useful markers for evaluating the severity of congestive heart failure. METHODS: Serum concentrations of myosin light chain I (MLC-I), heart fatty acid binding protein (H-FABP), creatine kinase isoenzyme MB (CK-MB), and troponin T (TnT) and plasma concentrations of brain natriuretic peptide (BNP) were determined in 48 patients with acute deterioration of congestive heart failure, both before and after effective treatment. RESULTS: Before treatment, MLC-I (mean (SEM) 3.2 (2.2) microg/l), H-FABP (9.0 (3.5) microg/l), TnT (30 (21) ng/l), and BNP (761 (303) ng/l) were higher than the normal reference range, and concentrations of CK-MB (5.4 (2.9) microg/l) were near normal. Treatment of congestive heart failure with conventional medication significantly decreased the concentrations of MLC-I (1.2 (0.3) microg/l, p < 0.0001), H-FABP (6.0 (2.0) microg/l, p < 0.0001), CK-MB (2.9 (1.5) microg/l, p < 0.0001), TnT (9 (1) ng/l, p < 0.001), and BNP (156 (118) ng/l, p < 0.0001). The decreases in H-FABP and CK-MB concentrations after treatment correlated with the decrease in BNP concentrations (p < 0.05). The absolute concentrations of MLC-I, H-FABP, CK-MB, and TnT correlated positively with those of BNP (p < 0.01). CONCLUSIONS: These findings suggest that MLC-I, H-FABP, CK-MB, and TnT may be used as reliable markers for the evaluation of the severity of congestive heart failure.
Authors: C M Wei; D M Heublein; M A Perrella; A Lerman; R J Rodeheffer; C G McGregor; W D Edwards; H V Schaff; J C Burnett Journal: Circulation Date: 1993-09 Impact factor: 29.690
Authors: K Sohmiya; T Tanaka; R Tsuji; K Yoshimoto; Y Nakayama; Y Hirota; K Kawamura; Y Matsunaga; S Nishimura; H Miyazaki Journal: J Mol Cell Cardiol Date: 1993-12 Impact factor: 5.000
Authors: C A Beltrami; N Finato; M Rocco; G A Feruglio; C Puricelli; E Cigola; F Quaini; E H Sonnenblick; G Olivetti; P Anversa Journal: Circulation Date: 1994-01 Impact factor: 29.690
Authors: K Komamura; T Sasaki; A Hanatani; J Kim; K Hashimura; Y Ishida; Y Ohkaru; K Asayama; T Tanaka; A Ogai; T Nakatani; S Kitamura; K Kangawa; K Miyatake; M Kitakaze Journal: Heart Date: 2005-12-30 Impact factor: 5.994
Authors: Kyung Su Kim; Hui Jai Lee; Kyuseok Kim; You Hwan Jo; Tae Yun Kim; Jin Hee Lee; Joong Eui Rhee; Gil Joon Suh; Mi Ran Kim; Christopher C Lee; Adam J Singer Journal: J Korean Med Sci Date: 2010-12-22 Impact factor: 2.153
Authors: Ming Wai Hung; Zai Jun Zhang; Shang Li; Benson Lei; Shuai Yuan; Guo Zhen Cui; Pui Man Hoi; Kelvin Chan; Simon Ming Yuen Lee Journal: Evid Based Complement Alternat Med Date: 2012-08-05 Impact factor: 2.629